Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?

被引：22

作者：

Deen, Jacqueline ^{[1
]}

Lopez, Anna Lena ^{[1
]}

Kanungo, Suman ^{[2
]}

Wang, Xuan-Yi ^{[3
,4
,5
]}

Dang Duc Anh ^{[6
]}

Tapia, Milagritos ^{[7
]}

Grais, Rebecca F. ^{[8
]}

机构：

[1] Univ Philippines, Natl Inst Hlth, Inst Child Hlth & Human Dev, Manila, Philippines

[2] ICMR, Natl Inst Cholera & Enter Dis, Div Epidemiol, Kolkata, W Bengal, India

[3] Fudan Univ, MoE, Key Lab Med Mol Virol, Shanghai, Peoples R China

[4] Fudan Univ, MoH, Shanghai, Peoples R China

[5] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China

[6] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam

[7] Univ Sch Med, Ctr Vaccine Dev, Baltimore, MD USA

[8] Epicentre, Dept Res, Paris, France

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 02期

关键词：

Rotavirus; rotavirus vaccine; rotavirus vaccination; DOUBLE-BLIND; INFECTION; CHILDREN; EFFICACY; IMMUNOGENICITY; INFANTS; AFRICAN; IMPACT; SAFETY; TRIAL;

D O I：

10.1080/21645515.2017.1403705

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

There are two internationally available WHO-prequalified oral rotavirus vaccines (Rotarix and RotaTeq), two rotavirus vaccines licensed in India (Rotavac and Rotasiil), one in China (Lanzhou lamb rotavirus vaccine) and one in Vietnam (Rotavin-M1), and several candidates in development. Rotavirus vaccination has been rolled out in Latin American countries and is beginning to be deployed in sub-Saharan African countries but middle- and low-income Asian countries have lagged behind in rotavirus vaccine introduction. We provide a mini-review of the leading newer-generation rotavirus vaccines and compare them with Rotarix and RotaTeq. We discuss how the development and future availability of newer-generation rotavirus vaccines that address the programmatic needs of poorer countries may help scale-up rotavirus vaccination where it is needed.

引用

页码：495 / 499

页数：5

共 8 条

[1] The Challenges and Opportunities of Next-Generation Rotavirus Vaccines: Summary of an Expert Meeting with Vaccine Developers
Chen, Jessie
Grow, Stephanie
Iturriza-Gomara, Miren
Hausdorff, William P.
Fix, Alan
Kirkwood, Carl D.
VIRUSES-BASEL, 2022, 14 (11):
[2] Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?
Steele, A. D.
Victor, J. C.
Carey, M. E.
Tate, J. E.
Atherly, D. E.
Pecenka, C.
Diaz, Z.
Parashar, U. D.
Kirkwood, C. D.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1215 - 1227
[3] Disease burden and seasonal impact of improving rotavirus vaccine coverage in the United States: A modeling study
Ai, Chin-En
Steele, Molly
Lopman, Benjamin
PLOS ONE, 2020, 15 (02):
[4] Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines
Luna-Casas, Gerardo
Juliao, Patricia
Carreno-Manjarrez, Roberto
Castaneda-Prado, Andres
Yolanda Cervantes-Apolinar, Maria
Navarro-Rodriguez, Ricardo
Sanchez-Gonzalez, Gilberto
Cortes-Alcala, Ricardo
DeAntonio, Rodrigo
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1251 - 1259
[5] Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines
Lee, Benjamin
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (06) : 1787 - 1802
[6] Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough
Baber, Usman
Mehran, Roxana
CARDIOLOGY, 2017, 138 (02) : 73 - 75
[7] Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
Hausdorff, William P.
Price, Jessica
Debellut, Frederic
Mooney, Jessica
Torkelson, Andrew A.
Giorgadze, Khatuna
Pecenka, Clint
VACCINES, 2022, 10 (02)
[8] Reply letter in response to "Letter to the editor in response to: Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence, Martinelli D et al., Human Vaccines & Immunotherapeutics 2020" by Carias and colleagues
Marchetti, Federico
Martinelli, Domenico
Fortunato, Francesca
Prato, Rosa
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (10) : 3641 - 3642

← 1 →